Skip to main content

Table 3 Cohort characteristics stratified by mortality outcomes

From: Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study

  Survived (n = 180, %) Died (n = 244, %) p-value
Age (years)* 28.7 ± 15.3 31.8 ± 20.8 0.080
Sex
 Female 108 (60.0) 145 (59.4) 0.921
 Male 72 (40.0) 99 (40.6)
Length of Stay (days) 13, (10, 17) 4, (3, 6) 0.000
Country of Treatment
 Sierra Leone 119 (66.1) 171 (70.1) 0.399
 Liberia 61 (33.9) 73 (29.9)
Rapid diagnostic test for malaria results
 Positive 17 (9.4) 31 (12.7) 0.082
 Negative 94 (52.2) 101 (41.4)
 Not Tested 69 (38.3) 112 (45.9)
Cycle Threshold Value /Viral Load
 ≥22 (Low Viral Load) 81 (45.0) 41 (16.8) 0.000
  < 22 (High Viral Load) 50 (27.8) 109 (44.7)
 Missing 49 (27.2) 94 (38.5)
Treatments received first 48 hours of care
 Artemether-lumefantrine 169 (93.9) 207 (84.8) 0.005
 ORS 166 (92.2) 207 (84.8) 0.023
 Cefixime 163 (90.6) 197 (80.7) 0.006
 Multivitamins 121 (67.2) 140 (57.4) 0.044
 Ondansetron 48 (26.7) 63 (25.8) 0.911
 Vitamin C 164 (92.8) 219 (89.8) 0.740
 Zinc Sulphate 7 (3.9) 15 (6.1) 0.378
 Vitamin A 152 (84.4) 178 (73.0) 0.006
Signs & symptoms first 48 hours of care
 Abnormal Bleeding 42 (23.3) 80 (32.8) 0.039
 Coma 0 (0.0) 6 (2.5) 0.041
 Diarrhea 111 (61.7) 187 (76.6) 0.001
 Dysphagia 60 (33.3) 111 (45.5) 0.012
 Dyspnea 41 (22.8) 94 (38.5) 0.001
 Jaundice 2 (1.1) 23 (9.4) 0.000
 Anorexia 116 (64.4) 167 (68.4) 0.405
 Abdominal Pain 108 (60.0) 157 (64.3) 0.363
 Vomiting 104 (57.8) 150 (61.5) 0.483
  1. *Values represent mean with standard deviation
  2. Values represent median with interquartile range